BACKGROUND: Adults with chronic cardiopulmonary conditions are at increased risk of severe respiratory syncytial virus (RSV) disease. This study estimated the burden of RSV in adults 50-59 years of age (YOA) with chronic cardiopulmonary diseases in the United States (US).
METHODS: A multicohort Markov model was used to separately estimate annual RSV burden in adults 50-59 YOA in the US with chronic obstructive pulmonary disease (COPD) (n=3,299,241), heart failure (HF) (n=712,959), coronary artery disease (CAD) (n=2,865,359), and asthma (n=3,439,066). Discounted life-years (LY) and quality-adjusted life years (QALY) lost due to RSV-related death were estimated over the remaining lifetime. Model inputs included RSV epidemiology and healthcare resource use (HRU) patterns. Inputs were sourced from scientific literature and public data. Model outcomes included RSV acute respiratory illnesses (ARI), lower respiratory tract disease (LRTD), HRU, deaths, LYs, and QALYs lost.
RESULTS: The model estimated annual RSV-ARI cases of 184,459 (population with COPD), 39,740 (HF), 159,926 (CAD), and 192,385 (asthma), with 57% of cases being LRTD. These RSV-ARI cases were estimated to result in 10,281, 3,842, 6,947 and 5,191 hospitalizations annually, respectively for COPD, HF, CAD, and asthma populations. RSV-related deaths in these populations ranged from 296 for HF to 723 for COPD. Discounted QALY losses ranged from 4,129 to 12,106 for the HF and COPD populations, respectively, due to RSV-related morbidity and mortality. See Table 1 for results.
CONCLUSIONS: Adults 50-59 YOA with cardiopulmonary diseases experience significant RSV burden and this population may benefit from RSV prevention measures.
